A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS OF VEPDEGESTRANT (PF-07850327) IN ADULT PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT RELATIVE TO HEALTHY PARTICIPANTS WITH NORMAL HEPATIC FUNCTION

The purpose of the study is to look at how the body processes a study medicine called vepdegestrant in participants with loss of liver function relative to people with normal liver function.
This study is seeking participants who are:
* females who cannot have children or males
* between 18 and 70 years of age
* weigh more than 50 Kilograms (110 pounds)
* either healthy with normal liver function or have loss of liver function
All participants in this study will take one dose of vepdegestrant by mouth. This study looks at how the medicine is changed and removed from the body after being taken by the participants. The amount of vepdegestrant in participants with loss of liver function will be compared to the amount of vepdegestrant in participants with normal liver function.
All participants will stay at the study clinic for about 11 days and 10 nights.

Start Date18 Nov 2025

Sponsor / Collaborator

Pfizer Inc.

[+1]

NCT06911788

/ CompletedPhase 1

A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD, SINGLE-DOSE, CROSS-OVER STUDY TO ESTIMATE THE ABSOLUTE BIOAVAILABILITY OF VEPDEGESTRANT (ARV-471, PF-07850327) FOLLOWING ORAL AND INTRAVENOUS DOSING OF THE DRUG TO HEALTHY PARTICIPANTS

The purpose of this study is to learn how much of the study medicine called Vepdegestrant will reach the bloodstream when given orally compared to given intravenously.
This study is seeking participants who:
* are healthy males and healthy females who cannot have children.
* are 18 years or older.
* are healthy as decided by medical tests.
* have a body mass index (BMI) of 16 to 32 kilogram per meter squared.
* have a total body weight of more than 45 kilograms (99 pounds).
In Period 1, all participants will receive one dose of Vepdegestrant by IV. In Period 2, all participants will receive one dose of Vepdegestrant by mouth following a high-fat breakfast. The levels of Vepdegestrant in Period 1 will be compared to the levels of Vepdegestrant in Period 2 and the bioavailablility of the oral formulation of Vepdegestrant will be determined.
The study duration is 22 days and includes two periods. Participants will stay in the clinical research unit for 9 days (8 nights) during each period. A follow-up visit for each participant takes place at 28 to 35 days after taking the study medicine for the last time.

Start Date03 Apr 2025

Sponsor / Collaborator

Pfizer Inc.

[+1]

NCT06645938

/ CompletedPhase 1

A PHASE I, RANDOMIZED, OPEN-LABEL, 2-PERIOD, 2-TREATMENT, 2-SEQUENCE, CROSSOVER, SINGLE-DOSE STUDY IN HEALTHY ADULT PARTICIPANTS TO ESTIMATE THE BIOAVAILABILITY OF AN VARIANT (HIGH HARDNESS) TABLET OF VEPDEGESTRANT (ARV-471, PF-07850327) RELATIVE TO THE REGISTRATIONAL TABLET

The purpose of the study is to compare the amount vepdegestrant available from two different tablet formulations under fed conditions in healthy adult participants; 200 mg vepdegestrant alternative tablet formulation compared to 200 mg vepdegestrant standard tablet formulation.
This study is seeking male or female participants of non-childbearing potential age who:
* are 18 years or older
* are healthy as decided by medical tests.
* have a Body mass index (BMI) of 16 to 32 kilogram per meter squared; and a total body weight of more than 45 kilograms (99 pounds).
All participants will be put into groups to receive one of the 2 treatments in each period. This study will consist of 2 treatment sequences:
* Sequence 1: Single 200 mg dose of vepdegestrant registrational tablet in Period 1, followed by a single 200 mg dose of vepdegestrant variant tablet in Period 2.
* Sequence 2: Single 200 mg dose of vepdegestrant variant tablet in Period 1, followed by a single 200 mg dose of vepdegestrant registrational tablet in Period 2.
Participants will be in the study for about 11 weeks.

Start Date16 Oct 2024

Sponsor / Collaborator

Pfizer Inc.

[+1]

100 Clinical Results associated with Vepdegestrant

100 Translational Medicine associated with Vepdegestrant

100 Patents (Medical) associated with Vepdegestrant

Literatures (Medical) associated with Vepdegestrant

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer

Review

Author: Babu, Basuvan ; Byran, Gowramma ; Rajagopal, Kalirajan ; Fanai, Hannah Lalengzuali

Breast cancer is one of the most significant health issues in the world, and resistance to treatment and a lack of targets that can be addressed with drugs limit the effectiveness of the existing treatment options. The development of proteolysis-targeting chimeras (PROTACs) has shifted the concept of occupancy-based inhibition toward event-based targeted protein degradation. Avoiding ubiquitin-proteasome hijacking, PROTACs target disease-relevant proteins to E3 ligases, allowing them to be catalytically degraded, thereby eliminating formerly undruggable or resistant targets. Their modular design, consisting of a warhead, linker, and E3 ligase ligand, eases rational design, but there are still difficulties, including hook effects, poor pharmacokinetics, and off-target toxicity. PROTACs have been known to undergo evolution, such as PHOTACs, CLIPTACs, and RIBOTACs, which have expanded therapeutic approaches. Clinical trial molecules such as ARV-471 have demonstrated an effective role in the degradation of ER+, showcasing their broader significance in HER2 by degrading BRD4, CDK, and PD-L1. However, a knowledge gap exists that limits our understanding of E3 ligases, constraining their tissue specificity and metabolism. Prospective directions focus on computational strategies to design E3 ligase-based PROTAC prodrugs, nanostructured PROTACs, and test them in vivo using organoids and xenograft models. Overall, PROTACs can become a novel therapeutic approach in the treatment of breast cancer.

01 Nov 2026·DRUGS

Vepdegestrant: First Approval

Review

Author: Fung, Simon

Vepdegestrant (VEPPANU; formerly ARV 471) is a novel PROteolysis TArgeting Chimera (PROTAC) that is able to simultaneously bind the estrogen receptor (ER) and an E3 ubiquitin ligase complex, resulting in polyubiquitination of the ER and its subsequent degradation via a proteasome. It is being developed by Arvinas and Pfizer primarily as a treatment for ER+, HER2- breast cancer. In May 2026, vepdegestrant received its first global approval in the USA for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. This article summarizes the milestones in the development of vepdegestrant leading to its first approval in this indication.

01 Nov 2026·JOURNAL OF CONTROLLED RELEASE

Effects of intestinal permeation enhancers on solubilization and epithelial transport of the proteolysis targeting chimera (PROTAC) ARV-471 in rats

Article

Author: Koziolek, Mirko ; Ortiz, Benjamín J ; Indulkar, Anura S ; Borchardt, Thomas ; Sjöblom, Markus ; Dahlgren, David ; Hedeland, Mikael ; Niessen, Janis ; Lennernäs, Hans

The molecular properties of proteolysis targeting chimeras (PROTACs) often fall outside the 'drug-like' rule of five (Ro5) chemical space, associated with poor intestinal solubility, permeability, and absorption. While formulation strategies have primarily focused on solubility enhancement, the intrinsic permeability barriers of PROTACs and the use of permeation enhancers to modulate them remain largely unexplored. This in vivo rat study assessed the potential of permeation enhancers to improve the intestinal absorption of ARV-471, a model PROTAC characterized by low solubility and permeability (BCS class IV). Intestinal absorption was determined based on plasma drug exposure (AUC_0-4h) following intraduodenal administration of an amorphous nanosuspension of ARV-471 (2.5 mg/kg), either alone or co-administered with three structurally diverse permeation enhancers (22 mg/kg): salcaprozate sodium (SNAC), lauroyl-l-carnitine (LLC), and sodium caprate (C10). The direct impact of these enhancers (4.4 mg/mL) on effective intestinal permeability was quantified using single-pass intestinal perfusion. These in vivo experiments were complemented by in vitro characterization of the colloidal properties and solubilization potential of ARV-471 in formulations with and without permeation enhancers. This integrated approach allowed the effects of epithelial permeation enhancement to be deconvoluted from those driven by luminal solubilization and dissolution. SNAC increased plasma AUC_0-4h 1.7-fold and enhanced permeability 2.5-fold, with negligible effects on drug solubilization. In contrast, LLC exhibited a dual mechanism, increasing AUC_0-4h 2.5-fold and permeability 2.2-fold, while simultaneously boosting apparent solubility 19-fold. C10 demonstrated only modest effects on absorption, likely related to membrane perturbation. Collectively, these findings demonstrate that permeation-enhancing excipients may improve the oral bioavailability of PROTACs and other BCS Class IV compounds by enhancing luminal solubilization and/or epithelial permeability.

163

News (Medical) associated with Vepdegestrant

22 Oct 2026

·www.biopharmadive.com

Protein degrader specialist Lycia prices $318M IPO

Lycia Therapeutics, a maker of protein degrading medicines, has banked nearly $318 millionin an initial public offering, the latest in a run of more than two dozen drugmakerIPOs in 2026.Like many other biotechs to go public this year, Lycia surpassed its projections, selling about 3 million more shares than it had anticipated. About two-thirds of the sectors IPOs in 2026 have exceeded $250 million in proceeds, according to BioPharma Dive data.Shares of Lycia begin trading Friday on the Nasdaq under the ticker symbol LYCA.Lycia was founded in part by Nobel Prize winner Carolyn Bertozzi, a pioneer in so-called click chemistry, a way to make new drugs by snapping together disparate molecules. The biotechs drugs, dubbed LYTACs, or lysosomal targeting chimeras, are designed to find harmful proteins outside of a cell and draw them inside to be destroyed. Lycia believes this approach can help it eliminate proteins that are inadequately addressed by current treatments, according to a regulatory filing.Lycia has three drugs in development, led by LCA-0061, an antibody-small molecule conjugate for allergic conditions, and LCA-0321, a protein-small molecule for Graves disease. Both are in Phase 1 testing, with data expected in 2027. Behind them is LCA-0062, another allergy-targeting drug, which could soon start testing and produce topline data as early as the second half of 2027.Both LCA-0061 and LCA-0062 go after immunoglobulin E, an antibody that defends the body from infections but can overreact and misidentify certain foods or pollen as a threat. In its IPO filing, Lycia argued that existing IgE-targeting medicines, such as Xolair, block but dont fully remove the antibody. They have other flaws, too, such as limited utility in key food allergy populations.LCA-0061, by comparison, might more deeply and durably wipe out IgE, the company said. Lycias follow-up drug, LCA-0062, could be dosed more flexibly than its predecessor.LCA-0321, on the other hand, degrades thyroid-stimulating hormone receptor autoantibodies that are prevalent in people with Graves disease. This strategy is different from existing medications, which primarily manage symptoms. Lycia also believes LCA-0321 could have an advantage over other emerging therapies in development, as it targets a key driver of Graves disease without broadly suppressing the immune system.Lycias research drew the interest of Eli Lilly, which paid $35 million up front in a 2021 collaboration focused on pain and other immune diseases. In addition, Lycia has raised $267 million in venture capital since its inception. Versant Ventures is its largest shareholder, owning around 19% of the company prior to the IPO.Targeted protein degradationa form of drugmaking that uses a cellular waste disposal system to trash tough-to-reach targets has become an increasingly hot area of drug research over the past two decades. Early specialists in the field, among them Arvinas,Kymera Therapeuticsand Parabilis Medicines, raised hundreds of millions of dollars in private funding and are now publicly traded.More recently, newer startups such as EpiBiologicsand Vicinitas Therapeutics have launched with plans to take the technology in different directions. And U.S. regulators in May approved the first protein-degrading PROTAC medicine, Veppanu, for breast cancer. '

Drug ApprovalIPOPhase 1PROTACs

18 Aug 2026

·www.biospace.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Aug. 11, 2026 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by a U.S. Food and Drug Administration (FDA)-authorized test, with disease progression following at least one line of endocrine therapy. "The commercial launch of VEPPANU marks an important milestone for Rigel and, more importantly, for patients living with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. In a pivotal trial, VEPPANU was generally well tolerated and demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus fulvestrant in this patient population. As the first and only FDA-approved PROTAC, VEPPANU introduces a novel mechanism of action and represents an important new treatment option for healthcare providers to consider with their patients," said Raul Rodriguez, Rigel's president and CEO. "Supported by our established oncology infrastructure, experienced commercial and medical affairs teams and comprehensive patient support programs, we are well positioned to execute a successful commercial launch of VEPPANU, allowing Rigel to deliver for patients while advancing our long-term growth strategy." VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to selectively degrade, rather than inhibit, disease-causing proteins. The recommended dosage of VEPPANU is 200 mg taken orally once daily. VEPPANU is immediately available through Rigel's network of specialty distributors and specialty pharmacies in the United States and Puerto Rico at $29,400 per 30-day supply. For those who qualify, Rigel offers patient assistance programs for patients prescribed VEPPANU by their doctor. RIGEL ONECARE®, the company's comprehensive patient support center, can help patients and physicians as they navigate insurance coverage requirements and provide financial assistance when needed and if eligible, along with other support programs. In May 2026, Rigel announced it entered into an exclusive, global license agreement with Arvinas, Inc. and Pfizer Inc. to develop, manufacture and commercialize VEPPANU. Breast cancer is the most common cancer in women in the United States, except for skin cancers.1 The estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) patient population represents the majority (70%) of breast cancer, where treatment with endocrine therapies (aromatase inhibitors) is the standard of care. While endocrine therapy remains a cornerstone of metastatic ER+/HER2- breast cancer treatment, up to 50% of patients treated with endocrine therapy and a CDK4/6 inhibitor acquire estrogen receptor 1 gene (ESR1) mutations, resulting in endocrine resistance and poor prognosis. Treatment options in second-line and later ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer setting include chemotherapy, selective estrogen receptor degraders (SERDs), and as of May 2026, vepdegestrant, the first and only FDA-approved oral PROteolysis TArgeting Chimera (PROTAC). Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalLicense out/in

14 Aug 2026

·www.biopharmadive.com

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Today, a brief rundown of news involving Capricor Therapeutics and Cytokinetics, as well as updates from Valneva, InduPro, Zealand Pharma and Rigel Pharmaceuticals that you may have missed.Capricor Therapeutics shares surged more than 60% on Friday after CEO Linda Marbn told analysts that the Food and Drug Administration appears open to reviewing an updated submission for its Duchenne muscular dystrophy cell therapy. An FDA panel last month voted against that therapy, deramiocel, in Duchenne-related cardiomyopathy, but expressed more support for the drugs impact on upper limb function. On an earnings call Thursday, Marbn said that, following discussions with regulators, the company intends to amend its application with new follow-up data that can support a refined indication. The agency is willing to review this amendment and extend the evaluation of deramiocel, Marbn said. It currently has an Aug. 22 decision deadline. Ben FidlerCytokinetics is escalating a turf war with Bristol Myers Squibb, announcing Thursday its suing the pharmaceutical giant to defend patents covering its newly launched heart drug Myqorzo. In court papers, Cytokinetics alleged Bristol Myers surprisingly got a particular patent covering certain methods of treating hypertrophic cardiomyopathy, including by using the active ingredient in Myqorzo, despite having zero involvement in its discovery or development. Cytokinetics claimed the move was an attempt to burden [it] with litigation and slow sales of Myqorzo, which competes with Bristol Myers Camzyos for market share. The company wants the court to declare Myqorzo doesnt infringe on that patent and to block Bristol Myers from threatening or launching related litigation. Ben FidlerShares of Valneva climbed about 20% on Friday after European drug regulators accepted an application for a Lyme disease vaccine its been developing with Pfizer. With the validation of that submission, the European Medicines Agency will begin reviewing Pfizer and Valnevas shot, PF-07307405. The partners have been planning to pursue global approvals despite mixed results they blamed on fewer-than-expected Lyme disease cases during the evaluation period of their key clinical trial. Stifel analyst Damien Choplain called EMAs endorsement a significant de-risking event for Valneva, with attention now turning to the vaccines approval prospects in the U.S. Ben FidlerBiotech startup InduPro said Wednesday it banked $77 million in a Series B round that would help the young company advance its portfolio of cancer and autoimmune drugs. InduPro recently took its lead program, a bispecific antibody drug-conjugate codenamed IDP-001, into early human testing in patients with advanced squamous non-small cell lung cancer and other solid tumors. The startup, which is headquartered in Seattle and Cambridge, Massachusetts, was backed by The Column Group, as well as Vida Ventures, Mercks corporate venture arm, Sanofi, Eli Lilly and others. Gwendolyn WuZealand Pharma is selling the rights it owns to a drug for a rare blood disorder to Royalty Pharma for $100 million. The deal announced Wednesday hands Royalty the economic interests and sales royalties Zealand holds in rusfertide, a polycythemia vera drug the Food and Drug Administration could approve in the third quarter. Zealand first obtained those rights through a 2012, peptide-focused research collaboration with Protagonist Therapeutics, which went on to develop rusfertide and partnered with Takeda Pharmaceutical in 2024. Zealand will keep a 0.25% royalty on global yearly rusfertide sales topping $1.5 billion, with Royalty getting 0.75% of sales exceeding that total. Delilah AlvaradoRigel Pharmaceuticals said its protein-degrading breast cancer drug Veppanu is now available for prescription in the U.S. Rigel acquired rights from Arvinas and Pfizer, which had initially aimed to develop the drug for a broad group of breast cancer patients before finding the treatment to be most beneficial in a subset of patients with a mutation to the ESR1 gene. The partners decided to offload the treatment afterwards, and cut a deal with Rigel following regulatory approval in May. Rigel priced a 30-day supply at $29,400. Delilah Alvarado '

VaccineDrug ApprovalLicense out/inCell TherapymRNA

100 Deals associated with Vepdegestrant

External Link

KEGG	Wiki	ATC	Drug Bank
D12628	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
ER-positive/HER2-negative/ ESR1-mutated breast cancer	United States	Rigel Pharmaceuticals, Inc.	01 May 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced breast cancer	Phase 3	United States	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	United States	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	China	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	China	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Japan	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Japan	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Australia	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Australia	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Brazil	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Brazil	Pfizer Inc.	09 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04606446 (ESMO2026)	Phase 1/2	Estrogen receptor positive breast cancer ER+/HER2−	13	vepdegestrant 200 mg + vepdegestrant 200 mg	dohewfowbl(xoplvrtxgm) = One pt in PRIFE3 had a DLT of G4 neutropenia kyayebqaye (hwkhsmdvtv ) View more	Positive	23 Oct 2026
NCT06206837 (TACTIVE-K, CTgov)	Phase 1/2	ER-positive/HER2-negative Breast Cancer	71	PF-07220060+Vepdegestrant (Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID)	egkpjrgdsr = npcaghhvmv lfzqfyjfzc (vkqftzmynx, ypeduchuok - eqfycxalna) View more	-	30 Sep 2026
				PF-07220060+Vepdegestrant (Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID)	egkpjrgdsr = oaizbzhnfr lfzqfyjfzc (vkqftzmynx, vmpkehbkbj - nvwlqdnhwg) View more
NCT05548127 (TACTIVE-U, ASCO2026)	Phase 1/2	ESR1-mutated \| ER+/human epidermal growth factor receptor 2-negative (HER2−)	37	AbemaciclibVepdegestrant + AbemaciclibVepdegestrant	cahpcxafxl(xlyhxhqgvq) = nwvmatpboj ijewxomprk (ulfzjcsqyq, 18.0 - 46.9) View more	Positive	29 May 2026
				Abemaciclib (ESR1m)	cahpcxafxl(xlyhxhqgvq) = mbbabivpdl ijewxomprk (ulfzjcsqyq, 25.8 - 65.8) View more
AACR2026	Phase 2/3	Hormone receptor positive HER2 negative breast cancer HR Positive \| HER2 Negative	16	Imlunestrant alone	lguwsdngci(ulqmjyfhme) = fvyhngqoit fpnsdbuhfk (fimyypmguo ) View more	Positive	21 Apr 2026
				Camizestrant 75mg	lguwsdngci(rbpsbfshmx) = vwobcrayvi plythyxuxg (hgggqcrqep ) View more
NCT05654623 (VERITAC-2, CTgov)	Phase 3	ER-positive/HER2-negative Breast Cancer	624	fulvestrant	afwccigtbs(bzorrvwdlk) = mloweybnts xhbrskzfnw (yiadhkgoxv, pckhbjnnpi - dxjpqfdjzn) View more	-	03 Feb 2026
NCT04072952 (SABCS2025)	Phase 1/2	ER-positive/HER2-negative Breast Cancer ESR1 mutation	138	Vepdegestrant (ER-positive/HER2-negative advanced breast cancer)	qqbwqlwkqg(gxwburvhai) = hdkfkjexba abpacyvqgz (iceqsnguyp ) View more	Positive	10 Dec 2025
NCT05549505 (TACTIVE-N, CTgov)	Phase 2	ER-positive/HER2-negative Breast Cancer	152	Surgical resection of breast tumor+ARV-471 (Arm A: ARV-471 (Experimental))	avqutxyhhb = jbtovbxfaf soczfwenkg (igumcyavwk, nbydofqnwt - zehmmimgvl) View more	-	29 Aug 2025
				Surgical resection of breast tumor+anastrozole (Arm B: Anastrozole)	avqutxyhhb = bibbjnaoti soczfwenkg (igumcyavwk, bpqavnajhs - aizrquqqdd) View more
NCT05654623 (VERITAC-2, Pubmed \| N Engl J Med)	Phase 3	Advanced breast cancer	624	Vepdegestrant 200 mg	flnfjnfetu(etbhcxjxqk) = in 2.9% and 0.7% of the patients, respectively ekqqfrodxz (uzsqujhtky ) View more	Positive	07 Aug 2025
				Fulvestrant 500 mg
NCT05654623 (VERITAC-2, ASCO2025 \| Company_Website) Manual	Phase 3	ER-positive/HER2-negative Breast Cancer ER Positive \| HER2 Negative	624	Vepdegestrant	qpukrcygux(lqtekyruwd) = ydbmfdfxou okrioqiecp (ahxfmlndko, 3.6–5.3) View more	Positive	30 May 2025
				fulvestrant	qpukrcygux(lqtekyruwd) = ynwlvamipr okrioqiecp (ahxfmlndko, 2.2–3.8) View more
NCT05654623 (VERITAC-2, Company_Website) Manual	Phase 3	ER-positive/HER2-negative Breast Cancer ESR1 Mutation	-	Vepdegestrant (ESR1 mutant)	wljjcgccyb(zetvpkgmjz) = The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population. fvkyordpnv (dvuxkfmdhr )	Negative	11 Mar 2025
				fulvestrant (ESR1 mutant)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis